Cooperation and development
Andrey Kaprin, general director of the Radiology Medical Research Center under the Russian Ministry of Health, confirmed to Radio Russia that the vaccine was developed in collaboration with several research institutes. This joint effort underscores Russia’s commitment to advancing cancer treatment through cutting-edge technology.
Promising preclinical results
Alexander Gintsberg, director of the Gamalia National Research Center for Epidemiology and Microbiology, reported to TASS that pre-clinical trials have shown the vaccine’s ability to inhibit tumor growth and prevent possible metastases. “Preclinical trials of the vaccine have shown that it effectively inhibits tumor growth and possible metastasis,” Kaprin told TASS.
Presidential endorsement
Earlier this year, Russian President Vladimir Putin highlighted advances in cancer research during the Moscow Forum on Future Technologies. “We are very close to creating a new generation of so-called cancer vaccines and immunomodulatory drugs,” he said, adding, “I hope to soon use them effectively as individualized treatment methods.” will be used.”
How mRNA vaccines target cancer.
An mRNA vaccine works by using a small piece of messenger RNA, a molecule that carries specific instructions from DNA to tell the body’s cells to produce proteins associated with cancer cells. This process triggers the immune system to recognize and attack these cancer cells, effectively training the body to target and eliminate the disease.
Unlike traditional vaccines that often rely on weakened or inactivated pathogens, mRNA vaccines use the body’s own cellular machinery to generate a precise immune response tailored to the specific cancer being treated. This innovative approach represents a significant shift in cancer treatment, potentially offering more effective and personalized treatment options.
Future prospects
The introduction of this mRNA cancer vaccine is an important moment in medical research and treatment. With its expected release in early 2025, Russia aims to provide an accessible and innovative treatment option for cancer patients, potentially changing the landscape of cancer treatment both domestically and globally. will